Asensus Surgical (FRA:2TX) ROCE % : -128.32% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Asensus Surgical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Asensus Surgical's annualized ROCE % for the quarter that ended in Dec. 2023 was -128.32%.

Asensus Surgical ROCE % Historical Data

The historical data trend for Asensus Surgical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical ROCE % Chart

Asensus Surgical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-112.13

-89.70

-51.61

-55.18

-100.66

Asensus Surgical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-61.27	-92.00	-107.13	-116.58	-128.32

Asensus Surgical ROCE % Calculation

Asensus Surgical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-71.635	/	( ( (109.554 - 9.831)	+	(54.182 - 11.58) )	/ 2 )
	=	-71.635	/	( (99.723	+	42.602)	/ 2 )
	=	-71.635	/	71.1625
	=	-100.66 %

Asensus Surgical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-62.564	/	( ( (66.271 - 11.359)	+	(54.182 - 11.58) )	/ 2 )
	=	-62.564	/	( ( 54.912	+	42.602 )	/ 2 )
	=	-62.564	/	48.757
	=	-128.32 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Asensus Surgical (FRA:2TX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Asensus Surgical ROCE % Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Asensus Surgical (FRA:2TX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (FRA:2TX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ASXC:USA

Address

1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703

Website

https://www.asensus.com

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Asensus Surgical (FRA:2TX) Headlines

No Headlines